Virtual Library

Start Your Search

Shigeto Hontsu



Author of

  • +

    P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 966)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P2.17-21 - Efficacy of Concurrent Carboplatin-Paclitaxel Chemoradiotherapy with 66 Gy for Elderly Patients with Stage III Non-Small Cell Lung Cancer (ID 12973)

      16:45 - 18:00  |  Author(s): Shigeto Hontsu

      • Abstract
      • Slides

      Background

      The common radiation dose for concurrent chemoradiotherapy for patients with stage III non-small cell lung cancer (NSCLC) is 60 Gy, however, we performed carboplatin-paclitaxel chemo radiotherapy with 66 Gy for elderly patients and examined whether that is feasible and effective.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      One hundred forty-four lung cancer patients underwent radiotherapy in our hospital between 2012 and 2013. In the present study, we analyzed thirty-eight patients with stage III NSCLC out of 144, excluding patients treated with palliative intent in the present study. They were divided into three treatment groups according to age, ECOG performance status (PS) and complications of each patient. Group A patients, who were younger than 70 years old, PS 0 or 1, and without any complications, received the concurrent cisplatin-docetaxel chemoradiotherapy with 60 Gy / 30 fractions. Group B, aged 70 years or older, PS 0 or 1, and without any complications, or younger than 70 and PS 2 or with complications, received the concurrent carboplatin-paclitaxel chemoradiotherapy with 66 Gy / 33 fractions. Group C, aged 70 years or older and PS 2 or over, and with complications, received radiotherapy alone with 70 Gy / 35 fractions. Three-dimensional conformal radiation treatment planning including elective mediastinal nodal irradiation was performed. To evaluate treatment outcomes among the three groups, we estimated overall survival (OS), progression-free survival (PFS) and local progression-free survival (LPFS), and analyzed the differences in these indices statistically by means of EZR (ver1.32). We also evaluated the toxicity among these three groups with NCI-CTCAE ver.4.0.

      4c3880bb027f159e801041b1021e88e8 Result

      The median of OS in Group A, B and C was 37.3 M, 40.4 M and 20.9 M, and that of PFS was 8.8 M, 17.9 M and 8.9 M, and that of LPFS was 25.9 M, 44.3 M and 22.8 M respectively. OS and LPFS were longer in Group A and B than C, and PFS was longer in B than C significantly (p<0.05). There were no significant differences between Group A and B in any indices. In Group A, Radiation pneumonitis and esophagitis were significantly less than Group B or C but blood toxicity was more (p<0.05).

      8eea62084ca7e541d918e823422bd82e Conclusion

      For elderly patients with stage III NSCLC, the concurrent carboplatin-paclitaxel chemoradiotherapy with 66 Gy is suggested to be feasible and effective.

      6f8b794f3246b0c1e1780bb4d4d5dc53

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.